Bis quaternary MRSA cephem derivatives

US6265394A · kind A · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Roman Z. Sterzycki · Madison, US
• Oak K. Kim · Cambridge, US
• Yasutsugu Ueda · Clinton, US
• Stanley D'Andrea · Middletown, US
• Dane M. Springer · Yardley, US

Key dates

• Filing date: Aug 4, 1999
• Grant date: Jul 24, 2001
• Expiry date: Aug 4, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Provided by the present invention are cephem derivatives represented by the general formula ##STR1## wherein Ar is an optionally substituted lipophilic phenyl, naphthyl or pyridyl group; L.sub.1 and L.sub.2 are (C.sub.1 -C.sub.6)alkylene optionally substituted with hydroxy or oxo and/or optionally interrupted with a vinylene group, S, O, aryl, heteroaryl, ##STR2## in which R.sub.1 is H or (C.sub.1 -C.sub.6)alkyl; A is CO.sub.2 H, PO.sub.3 H, SO.sub.3 H, tetrazolyl or ##STR3## x'.sup.- is a pharmaceutically acceptable anion; and Q is an quaternized nitrogen group. The derivatives are gram-positive antibacterial agents especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus.